Datafarm Announces the Release of Web-Based eCTD Viewer
Datafarm announces the release of a simple and cost effective Web-based eCTD viewer for companies of all sizes.
Philadelphia, 19 June 2006-Datafarm, the leading provider of electronic regulatory submission solutions, today announced the availability of eCTDViewer® Web Edition Version 3.0. This Web-based eCTD viewing solution includes support for all recent eCTD specifications and guidelines published by ICH, FDA, EMEA (including the most recent v1.2 specifications), Japan, Health Canada and Taiwanese agencies. This business tool offers zero desktop footprint and is designed meet the needs of companies of all sizes.
eCTDViewer Web Edition is built upon recognized technology standards such as HTML, XML, and JAVA. This combination of cross-platform technologies makes the application easy to deploy on both Windows and Linux servers, and allows it to support multiple application servers such as BEA WebLogic and Apache Tomcat. By using this standards-based approach, Datafarm has made it possible for any organization, regardless of size, to seamlessly incorporate eCTDViewer® Web Edition into their existing environment.
Datafarm's eCTD suite of applications includes eCTDBuilder®, used for submission compilation, and eCTDViewer® for submission review and paper dossier creation. This suite is currently used by over 40 companies in the US, EU, Canada and Japan who have successfully submitted over 800 submissions to the regulatory authorities.
Articles in this issue
about 19 years ago
Article
Phase Forward Delivers Enhanced Integration Capabilities as Part of Ongoing Adapter Strategyabout 19 years ago
Article
ClinPhone Exhibits its Clinical Trial Technology Solutions at 42nd DIA Annual Meetingabout 19 years ago
Article
Omnicomm Systems Inc., Introduces New TrialMaster V.4.0 at DIA's 42nd Annual MeetingNewsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025
- Generative AI Transforms Clinical Study Report Development
September 16th 2025